Gladius Pharmaceuticals is developing a novel, once-daily siderophore antibiotic for the treatment of multi-drug resistant pseudomonas aeruginosa and other prevalent Gram-negative bacteria.
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | Lumira Ven... | lumiravent... |
Mentions in press and media 1
| Date | Title | Description | Source |
| 22.06.2015 | Gladius Pharmaceuticals raises CAD $4.1 million to battle mu... | MONTRÉAL, Gladius Pharmaceuticals Inc., a Montréal-based biotechnology firm developing novel drugs t... | lumiravent... |